Evinacumab-dgnb 150 mg/ML [Evkeeza]
RxNorm 2478649

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2478649 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: evinacumab-dgnb 150 mg/ML [Evkeeza].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Evinacumab-dgnb 150 mg/ML [Evkeeza]
AUI:12539262
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Evinacumab-dgnb 150 mg/ML [Evkeeza]
(Atom ID: 12539262)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
evinacumab-dgnb 150 MG/ML [Evkeeza]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2478649
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12539262
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2478649
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Evinacumab-dgnb Injection


Evinacumab-dgnb is used in combination with other treatments to reduce the amount low-density lipoprotein (LDL) cholesterol ('bad cholesterol') and other fatty substances in the blood in adults and children 12 years of age or older that have homozygous familial hypercholesterolemia (HoFH; an inherited condition in which cholesterol cannot be removed from the body normally). Evinacumab-dgnb is in a class of medications called angiopoietin-like protein 3 (ANGPTL3) inhibitor monoclonal antibodies. It works by decreasing the production of LDL cholesterol and increasing the breakdown of LDL cholesterol and other fatty substances in the body. Accumulation of cholesterol and fats along the walls of your arteries (a process known as atherosclerosis) decreases blood flow and, therefore, the oxygen supply to your heart, brain, and other parts of your body. Lowering your blood level of cholesterol and fats may help prevent heart disease, angina (chest pain), strokes, and heart attacks.
[Learn More]


* Please review the disclaimer below.